Breast implant alternative startup Tensive receives €20 million EIB loan to advance REGENERA
Milan-based MedTech startup Tensive, the developer of REGENERA/SOFTAG bioresorbable scaffolds for breast reconstruction and tissue marking, has recieved a loan of €20 million in order to fund research and development, clinical studies, CE marking, manufacturing scale-up and commercialisation readiness. The convertible loan agreement was made with the European Investment Bank (EIB) – covering half…
Milan-based MedTech startup Tensive has secured a €20 million loan from the European Investment Bank (EIB) to advance their REGENERA/SOFTAG bioresorbable scaffolds for breast reconstruction and tissue marking. This convertible loan agreement constitutes half of the company's €40 million financing plan, earmarked for research and development, clinical studies, CE marking, manufacturing scale-up, and commercialization readiness.
The financing is supported under the Commission's InvestEU program. Tensive CEO Sanjay Kakkar stated that the EIB's commitment will help bring REGENERA from positive pivotal clinical results to a product available to European surgeons. While breast cancer implant markets are niche, Tensive's loan follows relevant financing activity in EU medical devices and regenerative technologies throughout 2026.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
